BACKGROUND/AIMS: A skull-mounted aiming device and integrated software platform has been developed for MRI-guided neurological interventions. In anticipation of upcoming gene therapy clinical trials, we adapted this device for real-time convection-enhanced delivery of therapeutics via a custom-designed infusion cannula. The targeting accuracy of this delivery system and the performance of the infusion cannula were validated in nonhuman primates. METHODS: Infusions of gadoteridol were delivered to multiple brain targets and the targeting error was determined for each cannula placement. Cannula performance was assessed by analyzing gadoteridol distributions and by histological analysis of tissue damage. RESULTS: The average targeting error for all targets (n = 11) was 0.8 mm (95% CI = 0.14). For clinically relevant volumes, the distribution volume of gadoteridol increased as a linear function (R(2) = 0.97) of the infusion volume (average slope = 3.30, 95% CI = 0.2). No infusions in any target produced occlusion, cannula reflux or leakage from adjacent tracts, and no signs of unexpected tissue damage were observed. CONCLUSIONS: This integrated delivery platform allows real-time convection-enhanced delivery to be performed with a high level of precision, predictability and safety. This approach may improve the success rate for clinical trials involving intracerebral drug delivery by direct infusion.
BACKGROUND/AIMS: A skull-mounted aiming device and integrated software platform has been developed for MRI-guided neurological interventions. In anticipation of upcoming gene therapy clinical trials, we adapted this device for real-time convection-enhanced delivery of therapeutics via a custom-designed infusion cannula. The targeting accuracy of this delivery system and the performance of the infusion cannula were validated in nonhuman primates. METHODS: Infusions of gadoteridol were delivered to multiple brain targets and the targeting error was determined for each cannula placement. Cannula performance was assessed by analyzing gadoteridol distributions and by histological analysis of tissue damage. RESULTS: The average targeting error for all targets (n = 11) was 0.8 mm (95% CI = 0.14). For clinically relevant volumes, the distribution volume of gadoteridol increased as a linear function (R(2) = 0.97) of the infusion volume (average slope = 3.30, 95% CI = 0.2). No infusions in any target produced occlusion, cannula reflux or leakage from adjacent tracts, and no signs of unexpected tissue damage were observed. CONCLUSIONS: This integrated delivery platform allows real-time convection-enhanced delivery to be performed with a high level of precision, predictability and safety. This approach may improve the success rate for clinical trials involving intracerebral drug delivery by direct infusion.
Authors: Tung T Nguyen; Yashdip S Pannu; Cynthia Sung; Robert L Dedrick; Stuart Walbridge; Martin W Brechbiel; Kayhan Garmestani; Markus Beitzel; Alexander T Yordanov; Edward H Oldfield Journal: J Neurosurg Date: 2003-03 Impact factor: 5.115
Authors: Nikunj K Patel; Martin Bunnage; Puneet Plaha; Clive N Svendsen; Peter Heywood; Steven S Gill Journal: Ann Neurol Date: 2005-02 Impact factor: 10.422
Authors: John T Slevin; Greg A Gerhardt; Charles D Smith; Don M Gash; Richard Kryscio; Byron Young Journal: J Neurosurg Date: 2005-02 Impact factor: 5.115
Authors: K S Bankiewicz; J L Eberling; M Kohutnicka; W Jagust; P Pivirotto; J Bringas; J Cunningham; T F Budinger; J Harvey-White Journal: Exp Neurol Date: 2000-07 Impact factor: 5.330
Authors: R H Bobo; D W Laske; A Akbasak; P F Morrison; R L Dedrick; E H Oldfield Journal: Proc Natl Acad Sci U S A Date: 1994-03-15 Impact factor: 11.205
Authors: Raymond T Bartus; Christopher D Herzog; Yaping Chu; Alistair Wilson; Lamar Brown; Joao Siffert; Eugene M Johnson; C Warren Olanow; Elliott J Mufson; Jeffrey H Kordower Journal: Mov Disord Date: 2010-11-18 Impact factor: 10.338
Authors: Kathryn L Holloway; Steven E Gaede; Philip A Starr; Joshua M Rosenow; Viswanathan Ramakrishnan; Jaimie M Henderson Journal: J Neurosurg Date: 2005-09 Impact factor: 5.115
Authors: Martin L Brady; Raghu Raghavan; Walter Block; Benjamin Grabow; Chris Ross; Ken Kubota; Andrew L Alexander; Marina E Emborg Journal: Stereotact Funct Neurosurg Date: 2015-02-18 Impact factor: 1.875
Authors: Waldy San Sebastian; Lluis Samaranch; Adrian P Kells; John Forsayeth; Krystof S Bankiewicz Journal: Neurotherapeutics Date: 2013-07 Impact factor: 7.620
Authors: Waldy San Sebastian; R Mark Richardson; Adrian P Kells; Clementine Lamarre; John Bringas; Philip Pivirotto; Ernesto A Salegio; Stephen J Dearmond; John Forsayeth; Krystof S Bankiewicz Journal: Hum Gene Ther Date: 2012-01-26 Impact factor: 5.695
Authors: Gabriele Mittermeyer; Chadwick W Christine; Kathryn H Rosenbluth; Suzanne L Baker; Philip Starr; Paul Larson; Paul L Kaplan; John Forsayeth; Michael J Aminoff; Krystof S Bankiewicz Journal: Hum Gene Ther Date: 2012-04-10 Impact factor: 5.695
Authors: Seunggu J Han; Krystof Bankiewicz; Nicholas A Butowski; Paul S Larson; Manish K Aghi Journal: Expert Rev Neurother Date: 2016-04-20 Impact factor: 4.618
Authors: R Mark Richardson; Adrian P Kells; Kathryn H Rosenbluth; Ernesto Aguilar Salegio; Massimo S Fiandaca; Paul S Larson; Philip A Starr; Alastair J Martin; Russell R Lonser; Howard J Federoff; John R Forsayeth; Krystof S Bankiewicz Journal: Mol Ther Date: 2011-02-22 Impact factor: 11.454